Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 2/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | ESRRA | P11474 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3120494 | 0.91 | NOTUM (0.54) | MIFNOTUMACKR3BRD4CNR2 | |
| SCHEMBL3112254 | 0.86 | ACKR3 (0.42) | MIFNOTUMACKR3 | |
| SCHEMBL3118064 | 0.84 | BRD4 (0.49) | FAAHBRD4CNR2 | |
| SCHEMBL3115990 | 0.84 | BRD4 (0.51) | BRD4CNR2 | |
| SCHEMBL3103956 | 0.76 | DRD4 (0.42) | MIFFAAHMGLLACKR3BRD4 | |
| SCHEMBL3107316 | 0.74 | ACKR3 (0.57) | MIFACKR3ESRRARIPK1 | |
| SCHEMBL3117580 | 0.74 | BRD4 (0.52) | NOTUMBRD4 | |
| SCHEMBL3099940 | 0.74 | ACKR3 (0.39) | FAAHMGLLACKR3BRD4 | |
| SCHEMBL3105246 | 0.72 | ACKR3 (0.41) | FAAHACKR3BRD4CNR2 | |
| SCHEMBL3116006 | 0.72 | BRD4 (0.52) | MIFBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
| EP-1867331-A1 | TRIAZOLE DERIVATIVE AND THE USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | MIF 4297/4885NOTUM 1897/4885FAAH 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.